Current and future treatments for Alzheimer's disease.
TLDR
Current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I–III trials are discussed.Abstract:
Alzheimer’s dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as ‘disease-modifying’ drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulati...read more
Citations
More filters
Journal ArticleDOI
Role of natural products for the treatment of Alzheimer's disease.
TL;DR: A review of the pathogenesis and the therapeutic goals of Alzheimer's disease can be found in this paper, where the available data on various plants and isolated natural compounds used to prevent and diminish the symptoms of AD is discussed.
Journal ArticleDOI
Current and emerging therapeutic targets of alzheimer's disease for the design of multi-target directed ligands
TL;DR: In the last decade, multi- target drugs have been increasingly investigated for their application to AD treatment, and it is likely that multi-target compounds will continue to be increasingly studied in the future as potential treatments for AD.
Journal ArticleDOI
Effects of neural stem cell transplantation in Alzheimer’s disease models
TL;DR: Results from studies involving NSC transplantation in AD models indicate that this strategy could serve as a new therapeutic approach, and the types of mouse modeling system that are available and the effect in each model after human-derived NSC (hNSC) or murine-derivedNSC (mNSC).
Journal ArticleDOI
Raman spectroscopy and machine learning for biomedical applications: Alzheimer's disease diagnosis based on the analysis of cerebrospinal fluid.
Elena Ryzhikova,Nicole M. Ralbovsky,Vitali Sikirzhytski,Oleksandr Kazakov,Lenka Halámková,Joseph F. Quinn,Earl A. Zimmerman,Igor K. Lednev +7 more
TL;DR: The reported Raman spectroscopic examination of CSF can complement current clinical tests, making early AD detection fast, accurate, and inexpensive, and further method validation on a larger scale is required to indicate the true strength of the approach.
Journal ArticleDOI
An Artificial Neural Network Integrated Pipeline for Biomarker Discovery Using Alzheimer's Disease as a Case Study
TL;DR: The proposed pipeline consists of analysing public data with a categorical and continuous stepwise algorithm and further examination through network inference to predict gene interactions and can reliably generate novel markers and further examine known ones and can be used to guide future research in Alzheimer's disease.
References
More filters
Journal ArticleDOI
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling,Paul S. Aisen,Laurel A. Beckett,David A. Bennett,Suzanne Craft,Anne M. Fagan,Takeshi Iwatsubo,Clifford R. Jack,Jeffrey Kaye,Thomas J. Montine,Denise C. Park,Eric M. Reiman,Christopher C. Rowe,Eric Siemers,Yaakov Stern,Kristine Yaffe,Maria C. Carrillo,Bill Thies,Marcelle Morrison-Bogorad,Molly V. Wagster,Creighton H. Phelps +20 more
TL;DR: A conceptual framework and operational research criteria are proposed, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies and it is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD.
Journal ArticleDOI
The Cholinergic Hypothesis of Geriatric Memory Dysfunction
Raymond T. Bartus,Raymond T. Bartus,Reginald L. Dean,Bernard Beer,Bernard Beer,Arnold S. Lippa,Arnold S. Lippa +6 more
TL;DR: Biochemical, electrophysiological, and pharmacological evidence supporting a role for cholinergic dysfunction in age-related memory disturbances is critically reviewed and an attempt has been made to identify pseudoissues, resolve certain controversies, and clarify misconceptions that have occurred in the literature.
Journal ArticleDOI
Global prevalence of dementia: a Delphi consensus study
Cleusa P. Ferri,Martin Prince,Carol Brayne,Henry Brodaty,Laura Fratiglioni,Mary Ganguli,Kathleen S. Hall,Kazuo Hasegawa,Hugh C. Hendrie,Yueqin Huang,Anthony F. Jorm,Colin Mathers,Paulo Rossi Menezes,Elizabeth Rimmer,Marcia Scazufca +14 more
TL;DR: Detailed estimates of dementia prevalence for each world region are believed to constitute the best currently available basis for policymaking, planning, and allocation of health and welfare resources.
Journal ArticleDOI
Revising the definition of Alzheimer's disease: a new lexicon.
Bruno Dubois,Howard Feldman,Howard Feldman,Howard Feldman,Claudia Jacova,Jeffrey L. Cummings,Steven T. DeKosky,Pascale Barberger-Gateau,André Delacourte,Giovanni B. Frisoni,Nick C. Fox,Douglas Galasko,Serge Gauthier,Harald Hampel,Gregory A. Jicha,Kenichi Meguro,John T. O'Brien,Florence Pasquier,Philippe Robert,Martin N. Rossor,Steven Salloway,Marie Sarazin,Leonardo Cruz de Souza,Yaakov Stern,Pieter Jelle Visser,Pieter Jelle Visser,Philip Scheltens +26 more
TL;DR: This paper aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities.
Journal ArticleDOI
Statins and the risk of dementia.
Hershel Jick,Gwen L. Zornberg,Gwen L. Zornberg,Susan S. Jick,Sudha Seshadri,David A. Drachman +5 more
TL;DR: Individuals of 50 years and older who were prescribed statins had a substantially lowered risk of developing dementia, independent of the presence or absence of untreated hyperlipidaemia, or exposure to nonstatin LLAs.
Related Papers (5)
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
John Hardy,Dennis J. Selkoe +1 more
Neuroinflammation in Alzheimer's disease
Michael T. Heneka,Monica J. Carson,Joseph El Khoury,Gary E. Landreth,Frederic Brosseron,Douglas L. Feinstein,Andreas H. Jacobs,Tony Wyss-Coray,Tony Wyss-Coray,Javier Vitorica,Richard M. Ransohoff,Karl Herrup,Sally A. Frautschy,Bente Finsen,Guy C. Brown,Alexei Verkhratsky,Alexei Verkhratsky,Alexei Verkhratsky,Koji Yamanaka,Jari Koistinaho,Eicke Latz,Eicke Latz,Annett Halle,Gabor C. Petzold,Terrence Town,Dave Morgan,Mari L. Shinohara,V. Hugh Perry,Clive Holmes,Clive Holmes,Nicolas G. Bazan,David J. Brooks,Stéphane Hunot,Bertrand Joseph,Nikolaus Deigendesch,Olga Garaschuk,Erik Boddeke,Charles A. Dinarello,John C.S. Breitner,Greg M. Cole,Douglas T. Golenbock,Markus P. Kummer +41 more